CTS is a manufacturer of sensors, connectivity components, and actuators, selling custom-engineered solutions to OEMs and tier one suppliers across transportation, industrial, medical, and aerospace and defense end markets. CTS organizes its products into three groups: Sense (sensors, pedals, switches, transducers), Connect (EMI/RFI filters, capacitors, frequency control products), and Move (piezo microactuators and rotary actuators). Roughly 86% of sales go through a direct sales engineer force, with the remainder through distributors and manufacturers' reps. Because most products are application-specific and require customer qualification, CTS typically supplies a given part for the life of a customer program once designed in. Transportation is the largest end market at roughly 43% of revenue, where CTS makes accelerator pedals, braking sensors, transmission position sensors, and chassis sensors — products designed to work across ICE, hybrid, and EV platforms. Medical (~16% of revenue), which focuses on piezo-based transducers for ultrasound imaging and therapeutic devices, is the fastest-growing segment. Industrial (~26%) and aerospace and defense (~15%) round out the business. CTS's stated strategy is to grow the higher-margin diversified markets — medical, industrial, and defense — while reducing transportation's relative weight, which management argues improves both growth and earnings quality. The 2024 acquisition of SyQwest added naval sonar and hydrophone capabilities, moving CTS from pure component supplier toward subsystems in defense. New transportation programs, including an electronic brake product, are expected to generate revenue in the 2027–2028 timeframe.
Read full business overview →Mid to long-term bullish thesis
View →Mid to long-term bearish thesis
View →Mid to long-term bull-bear debate
View → NEWSummary and scoring of the bull-bear debate
View →Find ideas with similar bull or bear theses
View →Investor-relevant company attributes
View →Key risks to the business
View →Comparisons of annual risk disclosures
View →